Study of Efficacy of Ribociclib After Progression on CDK4/6 Inhibition in Patients With HR+ HER2- Advanced Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer|Breast Carcinoma
Interventions: DRUG: LEE-011|DRUG: Fulvestrant|DRUG: Placebo
Sponsor: Melissa K Accordino
Collaborators: Novartis Pharmaceuticals